Study of Bronchiectasis and Associated Cardiovascular Comorbidities

Overview

Effect of cardiovascular comorbidities on disease severity and quality of life in Patients with acute exacerbation of non-cystic fibrosis bronchiectasis

Full Title of Study: “Effect of Cardiovascular Comorbidities on Disease Severity and Quality of Life in Patients With Acute Exacerbation of Non-cystic Fibrosis Bronchiectasis”

Study Type

• Study Type: Observational
• Study Design
  • Time Perspective: Cross-Sectional
• Study Primary Completion Date: September 1, 2023

Detailed Description

The study will include patients with bronchiectasis, and in an attempt to correlate the effect and burden of cardiovascular comorbidities in those patients, we will study the quality of life in those patients in comparison to the control group ( patients with bronchiectasis and without any other comorbidities) using SF-36 quality of life questionnaire. We will also study the inflammatory markers in both groups using D-dimer, BNP, and CRP and correlate them with the frequency of hospital admission, the severity of symptoms, and the general health state.

Interventions

• Device: Echocardiography
  • echocardiographic study of both groups

Arms, Groups and Cohorts

• Patient with bronchiectasis and cardiovascular comorbidities
  • Patients with Bronchiectasis had no comorbidities other than cardiovascular comorbidities during the study period.
• Patients with bronchiectasis and without cardiovascular comorbidities
  • Patients with Bronchiectasis had no comorbidities.

Clinical Trial Outcome Measures

Primary Measures

• assessment of BNP (Brain natriuretic peptide) pg/ml levels in patients with bronchiectasis and cardiovascular comorbidities.
  • Time Frame: March 2023 to September 2023
  • Serum BNP (Brain natriuretic peptide) pg/ml will be compared in both groups.
• Assessment of Quality of life in patients and control groups using The Short Form (36) Health Survey (SF-36)
  • Time Frame: March 2023 to September 2023
  • The Short Form (36) Health Survey will be performed in both groups. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.

Secondary Measures

• Hospitalization frequency in patient group compared to control group.
  • Time Frame: March 2023 to September 2023
  • Number of hospital admission in the last year will be compared in both groups.

Participating in This Clinical Trial

Inclusion Criteria

• Any Patients with Bronchiectasis had no comorbidities other than cardiovascular comorbidities during the study period. Exclusion Criteria:

• Any Patients who refuse to participate in the study. – Any other comorbidity or end-organ failure may affect the study's result.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 80 Years

Are Healthy Volunteers Accepted: No

Investigator Details

• Lead Sponsor
  • Assiut University
• Collaborator
  • Aliae AR Mohamed Hussein [ahussein
• Provider of Information About this Clinical Study
  • Principal Investigator: Ahmad Shaddad, Lecturer of pulmonary medicine Assuit university – Assiut University
• Overall Official(s)
  • Ahmad Shaddad, Principal Investigator, Assuit University Faculty of Medicine
  • Ahmad Shaddad, Principal Investigator, Assiut University Faculty of Medicine
• Overall Contact(s)
  • Shaadad Shaddad, MD, +201111171930, shaddad_ahmad@yahoo.com